Martin Frueh
A randomised non-comparative open label phase II trial of atezolizumab plus bevacizumab, with carboplatin-paclitaxel or pemetrexed, in EGFR-mutant non-small cell lung carcinoma with acquired resistance ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant non-small cell lung carcinoma
22.07.2020
Klinische Forschung - 22.07.2020 - 30.08.2028
Abgeschlossen
Projektleitung: Frueh Martin
Mitarbeiter/innen: Breuss Kim, Quinter Janine
Anti-PD-L1 antibody MEDI4736 in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC). A multicenter single-arm phase II trial.
22.04.2016
Klinische Forschung - 22.04.2016 - 28.08.2024
Abgeschlossen
Projektleitung: Frueh Martin
Mitarbeiter/innen: Breuss Kim, Quinter Janine